Australian Biopharmaceutical Company Immuron to Showcase Breakthrough Treatment for Travelers’ Diarrhea at Military Health Symposium
Melbourne-based biopharmaceutical company, Immuron Limited, is set to present its groundbreaking treatment for travelers’ diarrhea at The Military Health System Research Symposium (MHSRS) in Kissimmee, Florida from August 14 to 17, 2023. The MHSRS is an annual symposium that focuses on the unique medical needs of the Warfighter and brings together healthcare professionals, researchers, U.S. Department of Defense (DoD) leaders, decision-makers, and various funding bodies.
Immuron will attend the event as an Exhibitor and will showcase two posters. One poster titled ‘Clinical Evaluation of an Oral prophylactic for prevention of Travelers diarrhea in active-duty military assigned abroad,’ highlights the company’s clinical evaluation of an oral prophylactic to prevent travelers’ diarrhea in active-duty military personnel stationed overseas. The other poster, titled ‘Biologics license application of a bovine immunoglobulin supplement that prevents travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC)’ showcases Immuron’s collaborative work with the U.S. Department of Defense and the Medical Technology Enterprise Consortium (MTEC).
The symposium will also feature a poster from the Naval Medical Research Center (NMRC) on a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC), developed in collaboration with Immuron. The NMRC’s poster, titled ‘Research and Development of Hyperimmune Bovine Colostrum Products for the Prevention of Travelers’ Diarrhea,’ will shed light on their research efforts in combatting this common illness.
Infectious diarrhea is a prevalent illness among travelers visiting developing countries and U.S. troops deployed overseas. It not only affects daily performance but also decreases morale and operational readiness. While antibiotics have traditionally been the first line of treatment for infectious diarrhea, the rise in antibiotic resistance among enteric pathogens has posed a significant challenge. Additionally, medical professionals have recognized the post-infectious consequences of travelers’ diarrhea, including post-infectious irritable bowel syndrome (IBS) and autoimmune diseases. Therefore, the development of a preventative treatment that can defend against these enteric diseases has become a high priority objective for the U.S. Military.
Immuron Limited, an Australian biopharmaceutical company, is dedicated to developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory and infectious diseases. By presenting their breakthrough treatment for travelers’ diarrhea at the MHSRS, Immuron aims to draw attention to the pressing need for effective preventative measures against this condition and highlight their commitment to advancing military healthcare.
Disclaimer: This article has been written based on available information and does not constitute medical advice. It is recommended to consult with healthcare professionals for personalized guidance on the prevention and treatment of travelers’ diarrhea.
